AI Stock Memo: IDYA - IDEAYA Biosciences - RankAlpha

IDYA

AI Memo

IDEAYA Biosciences

As of 2026-07-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Darovasertib NDA filing path in H2 2026 • 2026-09-30

Expected move: +19%

Biggest risk

The bear case is that overall survival from OptimUM-02 was not yet mature, the key HLA*A2-positive update is still pending, and the rest of the pipeline remains early; additionally, OptimUM-10 enrollment timing was revised to end-2027 from prior H1 2027, which tempers execution confidence [#SEC-8K-2026-05-05].

Invalidation

Break below $24 or thesis failure.

What would change my mind?

The strongest supported bull argument is that OptimUM-02 moved darovasertib closer to IDYA’s first NDA, while the company still guided to about $973 million of cash and runway into 2030, giving room to fund multiple oncology programs without an immediate financing need [#SEC-8K-2026-05-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-07-02

Base target

$44

p=45%

Bull target

$58

p=30%

Bear target

$24

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Broader pipeline readouts and registrational starts can extend value beyond the lead asset
The strongest supported bull argument is that OptimUM-02 moved darovasertib closer to IDYA’s first NDA, while the company still guided to about $973 million of cash and runway into 2030, giving room to fund multiple oncology programs without an immediate financing need [#SEC-8K-2026-05-05].
At the July 1, 2026 anchor price of $36.17, shares trade below the packet’s median analyst target of $52.7857, but analyst count and fresh post-update revision data are unavailable, so the valuation gap should be treated as a cautious monitoring signal rather than proof of near-term rerating.

BearKey bullets

Follow-on proof points in HLA*A2-positive mUM and other pipeline programs are still pending, leaving the stock exposed to binary data risk through H2 2026 [#SEC-8K-2026-05-05].
Management revised full enrollment timing for the Phase 3 OptimUM-10 neoadjuvant trial to end-2027 from prior H1 2027, a reminder that development timelines can slip [#SEC-8K-2026-05-05].
Overall survival data for OptimUM-02 were not yet mature, so the lead-asset story still relies mainly on PFS/ORR strength rather than fully developed survival evidence [#SEC-8K-2026-05-05].

WatchKey bullets

Darovasertib NDA filing path in H2 2026

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $44 (p=45%)

Bull/Bear spread: +57% / -35%

Vs latest close: Bull +57% · Base +19% · Bear -35%

Scenario probabilities

Bull Target: $58 (p=30%)Base Target: $44 (p=45%)Bear Target: $24 (p=25%)

Commentary

Primary-source support is strong for the May operating update, but the broader packet has no trusted recent-news set, no usable analyst revision trail, and no meaningful social coverage. Combined with the deterministic prior that remains negative over 20-120 day windows, the setup reads as cautious H2 2026 catalyst monitoring rather than a high-conviction momentum long.

As of 2026-07-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Broader pipeline readouts and registrational starts can extend value beyond the lead asset

Scenarios

Bull Target (Scenario probability)

$58 / p=30% prob

Base Target (Scenario probability)

$44 / p=45% prob

Bear Target (Scenario probability)

$24 / p=25% prob

Price $37 as of 2026-07-10

Nearest Scenario: Base (∆ 19%)

Targets vs latest close: Bull +57% · Base +19% · Bear -35%

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
Darovasertib NDA filing path in H2 2026
Q1 2026 company materials said the Phase 2/3 OptimUM-02 trial met its primary endpoint, the FDA agreed to Real-Time Oncology Review, and IDEAYA is targeting NDA completion in H2 2026 for potential U.S. accelerated approval in 1L HLA*A2-negative metastatic uveal melanoma [#SEC-8K-2026-05-05].
Prob 70.00% • Move 18.00% • Priced-in 55.00%
EVENT2026-09-30
HLA*A2-positive mUM data update could broaden darovasertib use case
IDEAYA said it completed enrollment of about 100 HLA*A2-positive mUM patients in OptimUM-01 and plans a H2 2026 data presentation from more than 85 efficacy-evaluable patients, with the update intended to support potential label expansion and/or guideline inclusion [#SEC-8K-2026-05-05].
Prob 65.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Broader pipeline readouts and registrational starts can extend value beyond the lead asset
2026-12-31
Management flagged H2 2026 clinical updates for IDE849 and IDE034, mid-2026 combination work for IDE892 plus IDE397, and a planned registrational IDE849 monotherapy trial start by year-end 2026, giving IDYA multiple shots on goal but also raising execution complexity [#SEC-8K-2026-05-05].
Prob 55% • Move 12% • Priced-in 25%

Risks

Follow-on proof points in HLA*A2-positive mUM and other pipeline programs are still pending, leaving the stock exposed to binary data risk through H2 2026 [#SEC-8K-2026-05-05].
Management revised full enrollment timing for the Phase 3 OptimUM-10 neoadjuvant trial to end-2027 from prior H1 2027, a reminder that development timelines can slip [#SEC-8K-2026-05-05].
Overall survival data for OptimUM-02 were not yet mature, so the lead-asset story still relies mainly on PFS/ORR strength rather than fully developed survival evidence [#SEC-8K-2026-05-05].
Regulatory timing risk remains meaningful because the lead thesis depends on successful H2 2026 NDA execution under RTOR for accelerated approval [#SEC-8K-2026-05-05].
The June 23, 2026 8-K was governance-focused rather than an operating update, underscoring the current lack of incremental primary-source business news after the May earnings/business update [#8-K-2026-06-23].

Peers

Symbol	Summary
ELVN	Closest packet-listed operating comp as a clinical-stage oncology biotech, though indication overlap is limited; useful for sentiment on single-asset and data-driven valuation risk.
BEAM	Similar SMID-cap biotech risk profile with platform and pipeline optionality, but modality and development path differ materially from IDEAYA’s oncology portfolio.
ALMS	Primarily a capital-markets and clinical-stage biotech valuation comp rather than a direct operating peer; reinforces that the peer set here is loose.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-02